MacroGenics, Inc. (MGNX) is a publicly traded Healthcare sector company. As of May 21, 2026, MGNX trades at $4.48 with a market cap of $276.50M and a P/E ratio of -4.06. MGNX moved -0.88% today. Year to date, MGNX is +159.30%; over the trailing twelve months it is +184.08%. Its 52-week range spans $0.99 to $5.10. Analyst consensus is buy with an average price target of $6.33. Rallies surfaces MGNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes MGNX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $4.48 |
| Market Cap | $276.50M |
| P/E Ratio | -4.06 |
| EPS | $-1.10 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.10 |
| 52-Week Low | $0.99 |
| Volume | 3.95K |
| Avg Volume | 0 |
| Revenue (TTM) | $157.08M |
| Net Income | $-70.36M |
| Gross Margin | 0.00% |
5 analysts cover MGNX: 0 strong buy, 2 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.33.